Will you offer olaparib + abiraterone for all patients with metastatic castrate resistant prostate cancer based on results of PROPEL trial?
Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?
Community PollStarted
Will you offer olaparib + abiraterone for patients with metastatic CRPC based on PROPEL?
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
PROpel is clearly positive for its primary endpoint of delaying rPFS significantly in ALL first line mCRPC patients above and beyond abiraterone and prednisone alone. The delay of 8-10 months over an active comparator is significant both statistically and clinically, and is similar to the improvemen...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Va Portland Health Care System
Answered on
Not at this point. The trial results were interesting, but I am waiting for information as the data mature and more correlative work is done. (Honestly, I do not know what is being done at this point.)
Join for free or sign in to see the full answer